Dr. James Harding, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Albert Einstein College of Medicine of Yeshiva University (2007)
- Years since graduation
- 19
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 175
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2007Medical school: Albert Einstein College of Medicine of Yeshiva University
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 250863
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Sentara Obici Hospital Suffolk, VA
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
- Msk Harrison (132 clinicians)
- Memorial Developmental Chemo Group (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 175
- Services billed
- 803
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 664 | 144 |
| New patient office or other outpatient visit, 60-74 minutes | 50 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 25 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xarelto (rivaroxaban) Other prescribers in New York, NY | 51 |
| Lenvima (lenvatinib mesylate) | 51 |
| Pantoprazole Sodium Other prescribers in New York, NY | 50 |
| Ondansetron Hcl Other prescribers in New York, NY | 47 |
| Oxycodone Hcl Other prescribers in New York, NY | 29 |
| Dexamethasone Other prescribers in New York, NY | 29 |
| Ursodiol Other prescribers in New York, NY | 28 |
| Spironolactone Other prescribers in New York, NY | 25 |
| Pemazyre (pemigatinib) | 23 |
| Furosemide Other prescribers in New York, NY | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 21 payments worth $35,148 in total to this clinician.
| Jazz Pharmaceuticals Inc. | $19,751 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $5,470 |
| AbbVie Inc. | $3,820 |
| Eisai Inc. | $2,400 |
| E.r. Squibb & Sons, L.l.c. | $1,920 |
| Merck Sharp & Dohme LLC | $1,678 |
| AstraZeneca Ab | $60.00 |
| Servier Bioinnovation | $50.00 |
| Consulting Fee | $25,739 |
|---|---|
| Travel and Lodging | $7,941 |
| Compensation for services other than consulting (speaking, faculty) | $1,208 |
| Food and Beverage | $260 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $9,476 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Berlin, Germany · in-kind | $6,252 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee | $4,100 |
| AbbVie Inc. Jun 5, 2025 | Consulting Fee | $3,625 |
| Eisai Inc. Jul 2, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Consulting Fee | $1,920 |
| AstraZeneca Pharmaceuticals LP Jun 25, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,370 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $1,208 |
| Jazz Pharmaceuticals Inc. Jun 16, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $1,170 |
| Merck Sharp & Dohme LLC Jan 20, 2025 | Consulting Fee ENDOCRINOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $763 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| E.r. Squibb & Sons, L.l.c. Dec 8, 2025 | Consulting Fee | $1,920 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $9,476 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Berlin, Germany · in-kind | $6,252 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) ZIIHERA · HEMATOLOGY/ONCOLOGY | $1,208 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to Berlin, Germany · in-kind | $541 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to New York, NY · in-kind | $180 |
| Jazz Pharmaceuticals Inc. Nov 3, 2025 | Travel and Lodging ZIIHERA · HEMATOLOGY/ONCOLOGY · travel to New York, NY · in-kind | $180 |
| Merck Sharp & Dohme LLC Oct 8, 2025 | Consulting Fee ENDOCRINOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $610 |
| AstraZeneca Pharmaceuticals LP Sep 11, 2025 | Consulting Fee | $4,100 |
| Merck Sharp & Dohme LLC Sep 10, 2025 | Consulting Fee ENDOCRINOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $305 |
| Eisai Inc. Jul 2, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| AstraZeneca Pharmaceuticals LP Jun 25, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $1,370 |
| Jazz Pharmaceuticals Inc. Jun 16, 2025 | Consulting Fee ZIIHERA · HEMATOLOGY/ONCOLOGY | $1,170 |
| AbbVie Inc. Jun 5, 2025 | Consulting Fee | $3,625 |
| AbbVie Inc. Jun 5, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $44.56 |
| Merck Sharp & Dohme LLC Jan 20, 2025 | Consulting Fee ENDOCRINOLOGY Company’s descriptionProvided as part of a clinical research engagement. | $763 |
| Jazz Pharmaceuticals Inc. Jan 11, 2025 | Travel and Lodging travel to Berlin, Germany · in-kind | $743 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 6 companies. The companies reported $1,113,893 in research payments for these studies, mostly to the institutions running them.
- A Phase III,Randomized,Double Blind,Placebo Controlled,Multicenter,Global Study of Rilvegostomig in Combination with Chemotherapy as Adjuvant Treatment in Adult Participants After Resection of Biliary Tract Cancer wit…
AstraZeneca Pharmaceuticals LP - A Phase 3 Study, Open-label Randomized Trial of the Efficacy and Safety of Zanidatamab with Standard-of-Care Therapy Against Standard-of-Care Therapy Alone for Advanced HER2-positive Biliary Tract Cancer.
Jazz Pharmaceuticals Inc. - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie Inc. · Recruiting · NCT06084481 - Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 (Brigimadlin) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarc…
Boehringer Ingelheim Pharmaceuticals, Inc. - Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
AbbVie Inc. - A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Jazz Pharmaceuticals Inc. - A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination with Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma
E.r. Squibb & Sons, L.l.c. - Brightline-2: A Phase IIa/IIb, open-label, single-arm, multi-centre trial of BI 907828 (Brigimadlin) for treatment of patients with locally advanced / metastatic, MDM2 amplified, TP53 wild-type biliary tract adenocarc…
Boehringer Ingelheim Pharma GmbH & Co.kg
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.